Franchise Moat

Franchise Moat

Zoetis earns unusually durable economics — a 71.8% gross margin that has widened for a decade — because animal health has never grown a large generic industry the way human pharma did. That structural gap is real and shows up in the numbers. But the moat is franchise-specific and patent-bounded: older products have already lost most of their sales to generics, the top five brands make ~42% of revenue, and the 2026 evidence shows branded rivals now taking share out of Zoetis directly, because the market has stopped expanding to absorb them.

Why animal health resists generics

The foundation of Zoetis's economics is a fact about its industry, not about the company: there is no scaled generic threat. In its own words, "there is no large, well-capitalized company focused on generic animal health products that exists as a global competitor in the industry" [1]. Zoetis attributes this to three features of the market: each product opportunity is relatively small, distribution and education run directly through veterinarians, and the customer largely self-pays with no insurer pushing substitution [2].

That last point matters most. In human pharma, a patent expiry hands a formulary and a reimbursement system a reason to switch millions of scripts overnight. In a vet clinic, the prescriber and the dispenser are the same person, the brand is chosen at the point of care, and the pet owner pays cash. A generic still has to be detailed to the vet one clinic at a time. The result is that patent cliffs erode slowly, not abruptly — a real advantage, but one that slows the pace of erosion rather than preventing it.

The moat in the margin

A claimed moat has to appear in returns or pricing, or it is not established. Zoetis's does. Gross margin has climbed from 65.9% in 2016 to 71.8% in 2025 — a decade of widening despite acquisitions, currency, and a rising cost base.

Source: derived from reported revenue and cost of sales, FY2016–FY2025 10-Ks; recent gross margin confirmed in MD&A, where cost of sales fell to 28.2% of revenue in 2025 [3].

The mechanism behind the margin is pricing power, and management quantifies it. In the second quarter of 2024, stripping out hyperinflationary Argentina, Zoetis was adding "roughly 6 points of price and 3 points of volume" to revenue [4] — in that quarter, most of its growth came from charging more, not selling more units. By late 2024 it described growing "volume double digits while simultaneously taking price by being more targeted in our promotions" [5]. A business that raises price and holds share is exercising a moat; a commodity cannot.

Sources: gross margin per FY2025 MD&A [6]; top-five concentration [7]; Draxxin decline [8].

Franchise Concentration and Prior Erosion

The pricing power is not spread evenly. Two brands — Simparica and Apoquel — made roughly 16% and 12% of 2025 revenue; the top five (adding Cytopoint, Librela, and the ceftiofur line) reached about 42%, and the top ten about 57% [9]. The moat is really a handful of franchise moats, each with its own patent clock.

What happens when a clock runs out is on the record. Once generic tulathromycin arrived, US sales of the cattle antibiotic Draxxin fell 66%; the arthritis NSAID Rimadyl's US chewable sales fell 39% after generics launched [10]. The active-ingredient patents for Draxxin, the Excede/Naxcel ceftiofur line, and the anti-nausea drug Cerenia have all expired, with generics already on sale in multiple markets [11]. One of these — the ceftiofur line — sits inside the top-five revenue concentration cited above. Erosion is not a hypothetical for Zoetis; it is a repeating feature of the older book.

The offset has been a cadence of innovation that keeps replacing expiring exclusivity with newer, differentiated franchises. Cytopoint was the first canine monoclonal antibody for atopic dermatitis; Simparica Trio took Zoetis from fifth to second in triple-combination parasiticides; Librela created the injectable osteoarthritis-pain category and reached an 85% penetration rate faster than any product in company history [12]. Management's stated defense against new competitors is differentiation: "As we've seen with past generations of parasiticides, new entrants tend to accelerate the transition from older therapies. However, without meaningful differentiation, they do not take away market share" [13]. That claim is the moat's load-bearing assumption — and 2026 is testing it.

The test: share loss without market growth

In the first quarter of 2026 the franchises that carry the moat turned negative at the same time. Global companion-animal revenue fell 4%; key dermatology fell 11%, the osteoarthritis-pain antibodies fell 8%, and the Simparica line fell 1% — while companion diagnostics grew 10% and livestock grew 12% [14].

Source: Q1 FY2026 earnings call — global franchise revenue [15].

The important detail is not that competition arrived — Apoquel and Simparica have faced branded rivals for years — but how it is landing. Management named four dynamics: rising clinic prices with lower traffic, more price-sensitive pet owners, more aggressive competitor pricing across more markets, and, in contrast to prior cycles, new entrants that "have not yet translated into overall market expansion" [16]. That fourth point bears most directly on the moat. In every earlier parasiticide and dermatology cycle, a new competitor grew the category and Zoetis kept its slice of a bigger pie. In 2026 the pie stopped growing, so a rival's gain comes directly out of Zoetis's revenue. On the dermatology franchise, price "has played a larger role in the decision process," with share loss "amplified by a derm market with declining patient volume" [17].

The pricing lever is narrowing as a result. Zoetis entered 2026 planning 2–3% aggregate price and cut that expectation to 1–2%, conceding that the price gap to lower-cost competitors "is closing" [18]. Two of the four demand dynamics are macro (traffic, price sensitivity) and plausibly cyclical; the other two (more entrants, no market expansion) speak to the moat itself.

What the evidence supports

The moat is real and, by a decade of widening margins and demonstrated pricing power, has been wide. Two facts keep it from being impregnable: it is patent-bounded on a franchise-by-franchise basis — as the Draxxin and ceftiofur histories show — and its width now depends on continuous innovation rather than on structural protection from generics. The strongest fact for durability is that today's pressure is still branded competition, not generics: management states it is "not expecting generics in any of our key categories" — naming dermatology, pain, and parasiticides specifically — in the near term, even as generics have begun to bite the older Cerenia and Convenia brands [19]. Branded rivals must still earn each clinic; a moat that widened for ten years does not vanish in two quarters.

The strongest fact against is the one management itself flagged: for the first time, new entrants are taking share without expanding the market [20]. If that persists, the "differentiation defends share" assumption weakens, and the pricing power visible in the margin trend compresses. The read that would change here is a measurable one: whether Simparica and key-dermatology share stabilize as the companion-animal market returns to volume growth, or whether share keeps leaking in a flat market. Zoetis reports both, quarter by quarter, and the franchise concentration behind the de-rating means those two lines carry most of the answer.